Tovorafenib

OJEMDA

Kinase Inhibitor

NADAC/unit N/A

No Shortage Tier 1: 71.7% PA Req: 396.4%

Tovorafenib targets specific kinase enzymes involved in cancer cell growth and proliferation.

Covered Lives

Generic Manufacturers

DAY ONE BIOPHARMACEUTICALS INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Tovorafenib drfinder.aiFind doctors who prescribe Tovorafenib rxpbm.aiPBM spread analysis for Tovorafenib rxnews.aiLatest news about Tovorafenib

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.